Citations

Clear

941 citation(s) found for "Tefferi, A".

Cardiac tamponade in myelofibrosis: A Mayo clinic series of nine consecutive cases
Lavu, Sravanthi , Tefferi, Ayalew

Mayo Clinic

American Journal of Hematology | June 1, 2017 | Volume: 92 | Issue: 9 | Pages: No page available

10.1002/ajh.24800 | PMID 28568842 Get It

The 2016 revised World Health Organization definition of ‘myelodysplastic syndrome with isolated del(5q)’; prognostic implications of single versus double cytogenetic abnormalities
Gurney, Mark E. , Patnaik, Mrinal M. , Hanson, Curtis A. , Litzow, Mark R. , Al‐Kali, Aref , Ketterling, Rhett P. , Tefferi, Ayalew , Gangat, Naseema , Gurney, Mark , Ketterling, Rhett P

Mayo Clinic

British Journal of Haematology | April 17, 2017 | Volume: 178 | Issue: 1 | Pages: 57-60

10.1111/bjh.14636 | PMID 28419466 Get It

SummaryThe definition of the myelodysplastic syndrome (MDS) subtype ‘MDS with isolated del(5q)’ was expanded to include cases with one additional non‐chromosome 7 based cytogenetic abnormality in the 2016 revised World Health Organization classification. This study applied the revised definition to a large primary MDS cohort, and evaluated the prognostic impact of the additional cytogenetic abnormality. Seventy‐two of 1067 patients (7%) met the ‘MDS with isolated del(5q)’ criteria, 11 (1%) of whom had an additional cytogenetic abnormality. There was no survival difference between patients in whom del(5q) occurred alone, compared to those with one additional cytogenetic abnormality (P = 0·52).
Long-term analysis of the palliative benefit of 2-Chlorodeoxyadenosine (2-CdA) for myelofibrosis with myeloid metaplasia
Faoro, L. , Gertz, M. A., Tefferi, Ayalew , Mesa, Ruben A.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 6620-6620

10.1200/jco.2004.22.90140.6620 Get It

Ascorbic acid appears to increase the in vitro specificity and sensitivity of arsenic trioxide to the inhibition of primary myeloid colonies from patients wit
Tefferi, Ayalew , Powell, Heather L., Mesa, Ruben A. , Lasho, Terra L. , Kaufmann, Scott H.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 6619-6619

10.1200/jco.2004.22.90140.6619 Get It

Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms
Goel, Swati , Pereira, Arturo , Efficace, Fabio , Barbui, Tiziano , Tefferi, Ayalew , Cervantes, Francisco , Cervantes, Francisco , Paoli, Chiara , Iurlo, Alessandra , Vannucchi, Alessandro M. , Efficace, Fabio

Mayo Clinic

European Journal of Haematology | April 3, 2017 | Volume: 99 | Issue: 1 | Pages: 36-41

10.1111/ejh.12887 | PMID 28370510 Get It

AbstractObjectiveTo determine the financial and psycho‐social impact of participation in clinical trials of patients with BCR/ABL‐negative myeloproliferative neoplasms (MPN).MethodsAn international, observational cross‐sectional study was performed in 143 consecutive MPN patients (51% myelofibrosis, 36% polycythemia vera, 13% essential thrombocythemia), 68% from Italy, 17% from USA, and 15% from Spain.ResultsThirty‐five percent of patients reported having spent more money during the trial than in previous treatments and 21% having missed more workdays. Twelve percent replied that they would not have participated in the trial if the financial consequences would have been known beforehand. In 10% of the patients, the interpersonal relationships were more affected during the trial than in previous treatment but, overall, 91% subjects believed that participating in the clinical trial was worth the financial or emotional suffering. Concerning patients’ suggestions, 54% of them indicated that the number of visits required for the trial should be clearly specified in the informed consent, 60% recommended travel cost reimbursement, and 23% hotel cost reimbursement.ConclusionsPhysicians and pharmaceutical companies involved in clinical trials with patients with hematological diseases should be aware of these problems and make efforts to attenuate the socioeconomic burden of participation in the trials.
Monocytosis in polycythemia vera: Clinical and molecular correlates
Barraco, Daniela , Cerquozzi, Sonia , Gangat, Naseema , Patnaik, Mrinal M. , Finke, Christy M. , Hanson, Curtis A. , Ketterling, Rhett P. , Pardanani, Animesh , Tefferi, Ayalew , Lasho, Terra L. , Ketterling, Rhett P

Mayo Clinic

American Journal of Hematology | March 28, 2017 | Volume: 92 | Issue: 7 | Pages: 640-645

10.1002/ajh.24740 | PMID 28370365 Get It

AbstractMonocytosis (absolute monocyte count, AMC ≥ 1 × 109/L) might accompany a spectrum of myeloid neoplasms, other than chronic myelomonocytic leukemia (CMML). In the current study, we examined the prevalence, laboratory and molecular correlates, and prognostic relevance of monocytosis in polycythemia vera (PV). Among 267 consecutive patients with World Health Organization (WHO)‐defined PV, 55 (21%) patients displayed an AMC of ≥1 × 109/L and 18 (7%) an AMC of ≥1.5 × 109/L. In general, PV patients with monocytosis were significantly older and displayed higher frequencies of leukocytosis (81% vs. 50% at AMC ≥1 × 109/L) and TET2/SRSF2 mutations (57%/29% vs. 19%/1% at AMC ≥ 1.5 × 109/L). In univariate analysis, AMC ≥1.5 × 109/L adversely affected overall (OS; P = .004; HR 2.6, 95% CI 1.4‐4.8) and myelofibrosis‐free (MFFS; P = .02; HR 4.4, 95% CI 1.3‐15.1) survival; during multivariable analysis, significance was borderline sustained for OS (P = .05) and MFFS (P = .06). Other independent risk factors for OS included unfavorable karyotype (P = .02, HR 3.39, 95% CI 1.17‐9.79), older age (P < .0001, HR 3.34 95% CI 1.97‐5.65), and leukocytosis ≥15 × 109/L (P = .004, HR 2.04, 95% CI 1.26‐3.29). In conclusion, in the current study, we encountered a higher than expected prevalence of monocytosis in patients with PV and the mutation profile and age distribution of PV patients with monocytosis is akin to those of patients with CMML and might partly contribute to their worse prognosis.
Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia
Patnaik, Mrinal M. , Barraco, Daniela , Finke, Christy M. , Reichard, Kaaren K. , Hoversten, Katherine P., Ketterling, Rhett P. , Gangat, Naseema , Tefferi, Ayalew , Lasho, Terra L. , Ketterling, Rhett P

Mayo Clinic

American Journal of Hematology | March 17, 2017 | Volume: 92 | Issue: 6 | Pages: 542-548

10.1002/ajh.24722 | PMID 28314085 Get It

AbstractAtypical chronic myeloid leukemia (aCML) is an aggressive myeloid neoplasm with overlapping features of myelodysplastic syndromes (prominent granulocytic dysplasia) and myeloproliferative neoplasms (neutrophilic leukocytosis). We studied 25 molecularly‐annotated and World Health Organization defined aCML patients; median age 70 years, 84% males. Cytogenetic abnormalities were seen in 36% and gene mutations in 100%. Mutational frequencies were, ASXL1 28%, TET2 16%, NRAS 16%, SETBP1 12%, RUNX1 12%, ETNK1 8%, and PTPN11 4%. Fifteen patients (60%) had >1 mutation, while 9 (36%) had ≥3. The median overall survival (OS) was 10.8 months and at last follow up (median 11 months), 17 (68%) deaths and 2 (8%) leukemic transformations were documented. On univariate analysis, survival was adversely impacted by advanced age (P = .02), low hemoglobin (P = .01), red blood cell transfusion dependence (P = .03), high white blood cell count (P = .02), TET2 (P = .03), NRAS (P = .04), PTPN11 (P = .02) mutations and the presence of ≥3 gene mutations (P = .006); ASXL1, SETBP1, and ETNK1 mutations did not impact OS. In multivariable analysis, advanced age (P = .003) [age >67: HR 10.1, 95% CI 1.3‐119], low hemoglobin (P = .008) [HB< 10 gm/dL: HR 8.2, 95% CI 1.6‐23.2] and TET2 mutations (P = .01) [HR 8.8, 95% CI 1.6‐47.7] retained prognostic significance. We then used age >67 years, hemoglobin <10 gm/dL and the presence of TET2 mutations (each counted as one risk factor) to create a hazard ratio weighted prognostic model; effectively stratifying patients into two risk categories, low (0‐1 risk factor) and high (≥2 risk factors), with median OS of 18 and 7 months, respectively.
Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia
Behl, Deepti , Porrata, Luis F. , Elliott, Michelle A. , Hook, C. Christopher , Letendre, Louis, Pruthi, Rajiv K. , Tefferi, Ayalew , Litzow, Mark R. , Markovic, Svetomir N. , Kaufmann, Scott H.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 6553-6553

10.1200/jco.2005.23.16_suppl.6553 Get It

Der(6)t(1;6)(q21–23;p21.3): The most specific chromosomal translocation in myelofibrosis with myeloid metaplasia
Mahaffey, Victor, Spurbeck, Jack L., DeWald, Goron W, Tefferi, Ayalew , Dingli, David

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 6548-6548

10.1200/jco.2005.23.16_suppl.6548 Get It